Sofinnova Partners and Gustave Roussy launch first biotech company through Strategic Partnership
- Signadori Bio, a novel cell therapy platform, emerges from collaboration with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput
PARIS, France – March 18, 2025 — Sofinnova Partners, a leading European life sciences venture capital firm, in collaboration with Gustave Roussy, Europe’s leading cancer center, announces the creation of their first pioneering biotech company.
Signadori Bio, developed with scientific founders Dr. Jean-Luc Perfettini and Professor Nathalie Chaput, is a breakthrough cell therapy platform focused on transforming cancer treatment. This milestone marks a significant achievement in their strategic partnership, aimed at accelerating biotech innovation through rigorous evaluation and development of scientific research.
